Department of Biomedical Engineering and Institute for Computational Medicine, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA.
Cancer Biol Ther. 2010 Sep 15;10(6):582-7. doi: 10.4161/cbt.10.6.12537. Epub 2010 Oct 1.
Over 20,000 genes were recently sequenced in a series of 24 pancreatic cancers. We applied CHASM (Cancer-specific High-throughput Annotation of Somatic Mutations) to 963 of the missense somatic missense mutations discovered in these 24 cancers. CHASM identified putative driver mutations (false discovery rate ≤0.3) in three known pancreatic cancer driver genes (P53, SMAD4, CDKN2A). An additional 15 genes with putative driver mutations include genes coding for kinases (PIK3CG, DGKA, STK33, TTK and PRKCG), for cell cycle related proteins (NEK8), and for proteins involved in cell adhesion (CMAS, PCDHB2). These and other mutations identified by CHASM point to potential "driver genes" in pancreatic cancer that should be prioritized for additional follow-up.
最近在一系列 24 例胰腺癌中对 20000 多个基因进行了测序。我们应用 CHASM(癌症特异性高通量体细胞突变注释)对这 24 例癌症中发现的 963 个错义体细胞错义突变进行了分析。CHASM 在三个已知的胰腺癌驱动基因(P53、SMAD4 和 CDKN2A)中鉴定出了潜在的驱动突变(假发现率≤0.3)。另外还有 15 个具有潜在驱动突变的基因,包括编码激酶(PIK3CG、DGKA、STK33、TTK 和 PRKCG)、细胞周期相关蛋白(NEK8)和细胞黏附蛋白(CMAS、PCDHB2)的基因。这些和 CHASM 鉴定出的其他突变指向了胰腺癌中的潜在“驱动基因”,这些基因应优先进行进一步的研究。